**Salmonella enterica** serovar Choleraesuis vector delivering a dual-antigen expression cassette provides mouse cross-protection against *Streptococcus suis* serotypes 2, 7, 9, and 1/2

Yu-an Li1,2, Yanni Sun1,2, Yang Fu1,2, Yuqin Zhang1,2, Quan Li1,2, Shifeng Wang3 and Huoying Shi1,2,4*

**Abstract**

A universal vaccine protecting against multiple serotypes of *Streptococcus suis* is urgently needed to improve animal welfare and reduce the consumption of antibiotics. In this study, a dual antigen expression cassette consisting of SS2-SaoA and SS9-Eno was delivered by a recombinant *Salmonella* Choleraesuis vector to form the vaccine candidate rSC0016(pS-SE). SaoA and Eno were simultaneously synthesized in rSC0016(pS-SE) without affecting the colonization of the recombinant vector in the lymphatic system. In addition, the antiserum of mice immunized with rSC0016(pS-SE) produced a broader and potent opsonophagocytic response against multiple serotypes of *S. suis*. Finally, rSC0016(pS-SE) provided mice with a 100% protection against a lethal dose of parent *S. suis* serotype 2 and serotype 9, and provided 90% and 80% protection against heterologous *S. suis* serotype 7 or 1/2. These values were significantly higher than those obtained with rSC0016(pS-SaoA) or rSC0016(pS-Eno). Together, this study serves as a foundation for developing a universal vaccine against multiple serotypes of *S. suis*.

**Keywords:** *Salmonella* Choleraesuis vector, *Streptococcus suis*, dual antigen expression cassettes, universal vaccine

**Introduction**

*Streptococcus suis* is an important zoonotic pathogen, which causes substantial economic losses in the pig industry worldwide and many infections in humans [1, 2]. There are 35 serotypes of *S. suis*; serotypes 1/2, 2, 3, 7, and 9 (SS1/2, SS2, SS3, SS7, and SS9) are by far the most prevalent worldwide [2]. Vaccination is beneficial in reducing antibiotics consumption and slowing down antibiotic resistance development [3]. However, there are bottlenecks in the development of a *S. suis* vaccine. The expanded culture of *S. suis* requires a financially costly medium, which may render difficult the development of inactivated vaccines in less developed regions [3]. In addition, some vaccine candidates fail to induce opsonically active antibodies and thus fail to provide adequate protection [4–6]. Most importantly, existing vaccines lack cross-reactivity to ensure the protection against heterologous strains with multiple serotypes [7–10]. Therefore, developing an economical and effective universal vaccine is necessary to prevent disease with *S. suis* [1, 3].

An ideal *S. suis* vaccine should induce cross-protection against multiple serotypes. Among the immunogenic proteins tested as *S. suis* vaccine candidates, only Sao [11, 12], Eno [13], and PrsA [14] have been reported for their capacity to induce cross-protection. Conservative
Vaccines containing multiple antigens confer better protection than those containing a single antigen [17, 18]. A vaccine containing both muramidase-released protein (MRP) and extracellular factor (EF) protects pigs against challenge with S. suis serotype 2 virulent strain, while vaccines containing either MRP or EF alone were not protective [19]. Antigen combinations from different serotypes of BTV-Bluetongue virus not only provide protection against the parental serotype but also provide partial cross-protection against heterologous serotypes [20]. The combination of multiple antigens may bring about a synergistic effect. The multicomponent vaccine 5CVMB, which contains five serogroup B meningococcus (MenB) antigens, formulated with aluminum hydroxide induced strong immune responses. The bactericidal antibodies induced by 5CVMB were more potent than those induced by the individual antigen. The novel 5CVMB vaccine expands the vaccine coverage and avoids the selection of escape mutants [21].

Attenuated Salmonella vector as an antigen presentation platform can induce superior mucosal antibody response, which is critical against mucosal pathogens [22, 23]. In addition, the Salmonella vector can colonize the host lymphatic system, thereby continuously stimulating immune cells and ultimately inducing a long-term immune response [22–24]. Most importantly, attenuated Salmonella has known adjuvant properties that can enhance the humoral and cellular immune responses induced by foreign antigens, making it an excellent vector for presenting heterologous antigens [25, 26]. In our previous study, the attenuated S. Choleraesuis vector delivering SaoA from S. suis serotype 2 provided heterologous protection against SS7 in mice or piglets. However, it still could not induce protection against heterologous serotypes [12]. In this study, a dual expression cassette plasmid containing SS2-SaoA and SS9-Eno (pS-SE) was introduced into S. Choleraesuis rSC0016 to form the recombinant S. Choleraesuis vector rSC0016(pS-SE). The immunogenicity and the cross-protection efficiency of rSC0016(pS-SE) against multiple heterologous S. suis were evaluated in mice.

**Materials and methods**

**Ethical statement**

All animal experiments were authorized by the Department of Science and Technology of Jiangsu Province with a license number of SCXXK(SU) 2018-0009. All experimental procedures were approved by the Jiangsu Laboratory Animal Welfare and Ethics guidelines of the Jiangsu Administrative Committee of Laboratory Animals to minimize animal pain.

**Bacterial strains, plasmids, and culture conditions**

Bacterial strains and plasmids utilized in this study are described in Table 1. S. suis serotype 7 (SS7) virulent strain SH04805, S. Suis serotype 9 (SS9) virulent strain GZ0565, and S. Suis serotype 1/2 (SS1/2) virulent strain 2651 were kindly provided by Professor Huochun Yao (Nanjing Agricultural University). S. suis serotype 2 (SS2, CVCC3928) was purchased from China Veterinary Culture Collection Center. Plasmid pYA3493 is an Asd\(^+\) vector with a P\(_{mr}\) promoter. Plasmid pS-SE, derived from pYA3493, carries a dual antigen expression cassette consisting of SS2-SaoA and SS9-Eno. Plasmid pS-Eno, derived from pYA3493, carries an SS9-Eno. Plasmid pS-SaoA was described in our previous study [12]. S. Choleraesuis strains were prepared as previously described [12, 27]. The live attenuated S. Choleraesuis strain rSC0016 delivering plasmid pYA3493, pS-SaoA, pS-Eno, or pS-SE were grown in LB broth with both 0.2% L-arabinose and 0.2% D-mannose. LB broth and tetrathionate medium (BD Difco) were used for the enrichment of S. Choleraesuis from mouse tissues. Nutrient Broth (NB) and MacConkey agar (Difco) were used for phenotype characterization. When required, media were supplemented with 2,6-diaminopimelic acid (DAP; 50 µg/mL), L-arabinose (0.2% wt/vol), D-mannose (0.2% wt/vol) or sucrose (5% wt/vol). Bacterial growth was monitored with a spectrophotometer at OD\(_{600}\) and by direct plating for colony counts.

**Construction and plasmid stability of the attenuated S. Choleraesuis vector with plasmids pYA3493, pS-Eno and pS-SE**

S. Choleraesuis vector, rSC0016, was described in a previous study [12]. The codon-optimized SS9-eno was synthesized by TaKaRa Bio and cloned into pYA3493 with \(Pst\) I and \(Hind\) III to generate pS-Eno. An OmpA signal peptide was fused at the amino-terminal of Eno
in pS-Eno to replace the original Bla/ss signal peptide. Similarly, the codon-optimized SE operon fusion of SS2-saoA and SS9-eno was synthesized by TaKaRa Bio and cloned into pYA3493 with SmaI and HindIII to generate pS-SE. Bla/ss or OmpA signal peptides were fused at the amino terminal of SaoA or Eno in pS-SE, respectively. Subsequently, Asd+ plasmids pS-Eno and pS-SE were transformed into a live attenuated S. Choleraesuis vaccine strain, rSC0016, to generate rSC0016(pS-Eno) and rSC0016(pS-SE). To investigate the stabilities of recombinant plasmid pS-Eno and pS-SE in rSC0016, the strains harboring pS-Eno or pS-SE were maintained in an LB medium with 1:500 dilutions for 50 generations [27]. Plasmids pS-Eno and pS-SE were extracted at the 50th generation and confirmed with double enzymatic digestion. PCR verified mutations of the attenuated strain rSC0016 with correspondent primers. Production of Eno in rSC0016(pS-Eno) or SaoA and Eno in rSC0016 (pS-SE) were finally tested by western blot with corresponding antiserum [12, 28].

Western blot analysis of LacI, SaoA, and Eno expression
To evaluate arabinose dependent regulation of SaoA and Eno, rSC0016(pS-SE) were grown in NB medium with 0.2% L-arabinose (Sigma) at 37 °C. When the culture reached an OD600 of 0.8, it was diluted 1:100 into fresh NB without L-arabinose and grown to an OD600 of 0.8. This process was repeated 5 times. One mL of culture was collected from each passage and prepared for western blot analysis [12]. Briefly, the total protein samples were normalized and separated on a 10% (wt/vol) SDS-PAGE gel and transferred onto nitrocellulose membranes. Western blot analysis was performed using a rabbit anti-LacI, anti-SaoA and anti-Eno antisera, followed by HRP conjugated goat anti-rabbit polyclonal antibody (Sigma) [12, 28]. Densitometry was quantified using Image J2 software [29].

### S. Choleraesuis subcellular fractionation
To evaluate the subcellular localization of synthesized SaoA and Eno in rSC0016(pS-SaoA), rSC0016(pS-Eno), and rSC0016(pS-SE), mid-exponential growth phase cultures of the corresponding strains were harvested by centrifugation at 4 °C. Periplasmic fractions were prepared by modifying the lysozyme-osmotic shock method as previously described [30]. Briefly, cultures were grown in NB medium to an OD600 of 0.8 and induced with 0.5 mM IPTG (isopropyl-d-thiogalactopyranoside) for 3 h. The bacteria density was normalized by absorbance at OD600 to ensure that the samples in each lane contained the

### Table 1 Strains, plasmids and primers.

| Bacterial strains | Characteristics or sequences | Source, reference or function |
|-------------------|-----------------------------|-------------------------------|
| BL21              | For expression the recombinant plasmids | Invitrogen                     |
| χ7213             | thi-1 thi-1 leuB6 hisA21 lacY1 glnV44 asdA4 recA1 RP4 2-Tc::Mu pir; Km’ | [48]                           |
| rSC0016           | ΔPcrp527::TT araC,CP β-lactamase signal sequence-based periplasmic secretion plasmid | This study                     |
| Streptococcus suis serotype 2 | Wild type, virulent, CVCC3928 | Lab stock                     |
| Streptococcus suis serotype 7 | Wild type, virulent, SH04805 | Provided by Professor Huochun Yao |
| Streptococcus suis serotype 9 | Wild type, virulent, GZ0565 | Provided by Professor Huochun Yao |

| Plasmids | Characteristics or sequences | Source, reference or function |
|----------|-----------------------------|-------------------------------|
| pYA3493  | Asd+; pBR ori, PEC promoter | [49]                           |
| pS-SaoA  | pYA3493 with SaoA, PEC promoter | [29]                           |
| pS-Eno   | pYA3493 with Eno, PEC promoter | This study                     |
| pS-SE    | pYA3493 with a dual antigen expression cassettes consisting of SS2-SaoA and SS9-Eno, PEC promoter | This study                     |
| pET28a-SaoA | SS2-SaoA expression vector, T7 promoter, Km’ | [29]                           |
| pET28a-Eno | SS9-Eno expression vector, T7 promoter, Km’ | This study                     |

| Primers | Characteristics or sequences | Source, reference or function |
|---------|-----------------------------|-------------------------------|
| SS9-Eno-F | GGCTCGACAGGACCTACGCTATCGGC | The ORF of SS9-Eno            |
| SS9-Eno-R | GCCAAGCTTTCAGTTATAGAAAT      | The ORF of SaoA-Eno           |
| SE-F    | ATCCCGGGAACCTGATGGGGGCCAGG   | The ORF of SaoA-Eno           |
| SE-R    | CCCAAGCTTTCAGTTATAGAAAT      |                               |

| *Km’| Kanamycin resistance. | Underlined nucleotides denote enzyme restriction sites. |
same number of bacteria. One mL of culture was collected for western blot analysis. The supernatant fluid was filtered and saved for the analysis of secreted proteins. Equal volumes of periplasmic, cytoplasmic, and supernatant fractions and total protein lysate samples were separated on a 10% SDS-PAGE gel and transferred onto a nitrocellulose membrane for western blot analysis. Densitometry was quantified using Image J2 software [29].

Preparation of SaoA and Eno proteins
To obtain recombinant Eno from E. coli, the SS9-eno gene was optimized for E. coli-preferred codon and synthesized by TaKaRa Bio. SS9-eno gene was inserted into the pET-28a vector using Pst I and Hind III restriction enzymes. The pET-28a-Eno plasmid was transformed into E. coli strain BL21(DE3) for expression.

His-tagged SaoA or Eno fusion proteins were prepared as previously described [28]. Briefly, Escherichia coli strain BL21 carrying pET28a-SaoA or pET28a-Eno were grown to mid-log phase (OD_{600} values of 0.6–0.9) in LB medium with kanamycin at 30 °C and induced with 0.3 mM IPTG for 8 h. The recombinant SaoA or Eno proteins were purified by Ni-chelating affinity gel (Sigma) according to the instruction manual.

Distribution of S. Choleraesuis vector strains in BALB/c mice
The S. Choleraesuis strains, rSC0016(pYA3493), rSC0016(pS-SaoA), rSC0016(pS-Eno) and rSC0016(pS-SE), were grown statically overnight in LB broth supplemented with 0.2% L-arabinose and D-mannose at 37 °C. A 500 μL of overnight culture was inoculated into 50 mL of LB broth containing the appropriate supplements and grown with aeration to an OD_{600} of 0.85 to 0.9 at 37 °C. Cells were pelleted by centrifugation at room temperature (8000 rpm for 10 min). The pellets were resuspended in 300 μL of PBS. The colonization assay for recombinant S. Choleraesuis vector strains was performed as described previously [28]. Eighty mice were randomly divided into 5 groups, with 50 mice per group. Groups of mice were orally inoculated with the same strain after three weeks. Blood and vaginal secretion specimens from each mouse in a random subset (10 mice) in each group were collected 3 weeks after the first immunization and 2 weeks after boosting. Serum fractions were stored at −20 °C. Vaginal secretion specimens were collected by washing with 50 μL of PBS before storage at −20 °C.

Mouse immunization
Six-week-old female BALB/c mice were deprived of food and water for 4 h before oral administration of S. Choleraesuis strains. Food and water were returned to the animals 30 min later. To determine bacterial titers, dilutions of S. Choleraesuis strains were plated onto LB agar with 0.2% L-arabinose. Two hundred and fifty mice were randomly divided into 5 groups, with 50 mice per group. Groups of mice were orally inoculated with \( \pm 0.2 \times 10^9 \) CFU of S. Choleraesuis strains of rSC0016(pYA3493), rSC0016(pS-SaoA), rSC0016(pS-Eno), rSC0016(pS-SE) or an equal volume of PBS, respectively. Mice were boosted with the same dose of the same strain after three weeks. Blood and vaginal secretion specimens from each mouse in a random subset (10 mice) in each group were collected 3 weeks after the first immunization and 2 weeks after boosting. Serum fractions were stored at −20 °C. Vaginal secretion specimens were collected by washing with 50 μL of PBS before storage at −20 °C.

Enzyme-linked immunosorbent assay (ELISA)
The procedures used for antibodies measurement were described previously [12, 27]. Briefly, purified SaoA (50 ng per well) or Eno (50 ng per well) in sodium carbonate-sodium bicarbonate buffer (pH9.6) were coated in Nunc-Immuno MaxiSop 96-well plates (Corning, NY, USA). Plates were incubated overnight at 4 °C. Free binding sites were blocked with 0.5% BSA. A 100 μL volume of diluted serum was added to individual wells in duplicate and incubated for 3 h at room temperature. Plates were treated with Peroxidase-conjugated goat anti-mouse IgG, IgG1, or IgG2a (Abcam) for sera and IgA (BD) for vaginal secretions.

Opsonophagocytic assay
The OPA was performed as previously described [31]. Briefly, a random subset of 10 mice was selected from each group on the 14th day after the booster. Subsequently, serum from each mouse of each subset was collected and twofold serially diluted for opsonic killing assay. Porcine polymorphonuclear leukocytes (PMNs) were separated by Ficoll-Hypaque (Haoyang Biological Manufacture Co. Ltd., Tian-jin, China). Cell viability was evaluated higher than 90% by Trypan blue exclusion.
Log-phase SS2, SS7, SS9, and SS1/2 were opsonized with 50 μL of the diluted serum samples at 37 °C for 15 min, respectively. PMNs at a concentration of 1 × 10^7 cells/mL were mixed with equal volume (100 μL) of 1 × 10^7 CFU/mL opsonized bacteria. After incubation with PMNs for 1 h at 37 °C, serial dilutions of assay samples were plated onto THB agar and then cultured overnight at 37 °C. Bacteria were enumerated the following day. The serum dilution that led to killing of 50% of the assay bacteria was defined as the OPA titer. The mean of three independent CFU counts for each sample was used to calculate the survival ratio.

Mouse challenge with * S. suis *
On the 14th day after the booster, 10 mice in each group were challenged intraperitoneally with 10 × LD_{50} of SS2, SS7, SS9 and SS1/2, respectively. Mouse survival and health status were observed and recorded daily for 14 days. Tissue samples from the brain and lung were fixed in 4% paraformaldehyde. After paraffin embedding, tissue sections were cut and stained with hematoxylin and eosin (H&E). The histological sections of each mouse were scored pathologically as follows. For lung, 0: normal; 1: congestion; 2: interstitial thickening; 3: inflammatory cell infiltration in bronchial submucosa, 4: a mass of inflammatory cell infiltration in bronchial submucosa. For brain, 0: normal; 1: congestion; 2: a few inflammatory cells infiltrate the meninges; 3: a mass of inflammatory cells meninges; 4: meningeal hemorrhage with extensive inflammatory cell infiltration. This experiment was performed twice, with each group (50 mice) receiving approximately the same dose of vaccine. The results from both experiments were similar, and the data were pooled for analysis.

Statistical analysis
Statistical analyses on ELISA were presented as geometric means and standard deviations for all assays. A Mann–Whitney U Test (GraphPad Software, Inc.) was applied to compare the distribution of the * S. Choleraesuis* in tissues of mice and densitometric analysis. The log-rank (Mantel–Cox) test was used to compare the survival after the challenge. For all tests, a *P* < 0.05 was considered statistically significant.

Results
Construction of a dual expression cassette vector
SaoA protein homology among SS2, SS9, and SS1/2 serotypes is over 94.2%. Eno protein homology among these strains is over 99.8%. In addition, there was the same one amino acid difference between SS9-Eno and SS2-Eno, SS7-Eno, and SS1/2-Eno at position 250 (SS9-Eno: Phenylalanine; SS2-Eno, SS7-Eno, and SS1/2-Eno: Tyrosine).

To express SS2-*saoA* and SS9-*eno* on the same vector without interference, operon fusion of *saoA* and *eno* was separated by a ribosome binding sites (RBS) to form two separate expression cassettes under the regulation of the P_{trc} promoter (Figure 1A). Each gene has its own secretion signal. The dual expression cassette fragment was digested with *Sma* I and *Hind* III and cloned into the prokaryotic expression vector pYA3493 to form the expression plasmid pS-SE (SE represents for SaoA-Eno; Figure 1B).

Regularly delayed synthesis of SaoA and Eno in rSC0016(pS-SE)
Strain rSC0016 carries a Δ*relA*199::*araC* P_{BAD} lacI TT mutation, in which an arabinose-regulated *araC* P_{BAD} promoter controls the production of LacI. LacI inhibits the P_{trc} promoter, which drives the expression of *saoA* and *eno*. The combination of chromosomal lacI expression and P_{trc} transcripotional regulation of antigen gene expression comprises the delayed antigen synthesis system. To evaluate the delayed antigen synthesis regulated by LacI, the pS-SE plasmid was introduced into rSC0016. After growing in the NB medium containing 0.2% arabinose, the strain rSC0016(pS-SE) was passaged 4 times in the medium without arabinose. The equal loads of the samples were confirmed by measuring GroEL as an internal reference. As the number of passages increased, arabinose was gradually diluted and the synthesis of LacI decreased, while the synthesis of SaoA or Eno in strain rSC0016(pS-SE) gradually increased (Figure 1C). These results showed that the synthesis of both SaoA and Eno in the dual expression cassette was regulated by the delayed antigen synthesis system.

Growth characteristics and genetic stability of rSC0016(pS-SE)
The loading of foreign antigen may slow the vector growth, which may decrease the immunogenicity of the vectored antigen [22]. rSC0016(pS-SE) shared similar growth characteristics with rSC0016(pS-SaoA) or rSC0016(pS-Eno), suggesting that the dual expression cassette does not slow down the vector growth (Figure 1D). This result demonstrated that the dual expression cassette did not cause an obvious metabolic burden on the growth of rSC0016. To measure the stability of plasmid pS-SE in rSC0016, rSC0016 containing plasmid pS-SE were cultured for 50 generations. By PCR or endonuclease digestion, it was found that all rSC0016(pS-SE) colonies (200 clones/generation) contained pS-SE plasmids, indicating that pS-SE could be stably maintained in rSC0016 vaccine strains. The cells obtained from the 50th generation culture can synthesize similar amounts of SaoA and Eno to the first generation (data not shown),
suggesting that SaoA and Eno are stably synthesized in rSC0016(pS-SE).

**Expression levels of SaoA and Eno in rSC0016(pS-SE)**

Transcription and translation efficiency of the open reading frame at the far end of the operon in the dual expression cassette may be reduced [32]. To explore the expression of eno at the far end of the operon fusion in pS-SE dual expression cassette, the levels of SaoA or Eno production in the corresponding strains were compared by western blot densitometry. Bands specifically binding to SaoA or Eno antiserum could be detected in the cytoplasm, periplasm, and supernatant of rSC0016(pS-SE) (Figures 2A and B), suggesting that both SaoA and Eno can be synthesized simultaneously in rSC0016 and secreted into the periplasm and extracellularly. In addition, the synthesis of either SaoA (Figure 2C) located at the proximal end of the promoter or Eno (Figure 2D) located at the distal end of the promoter was not significantly different from SaoA or Eno with a single expression cassette.

**Colonization of mouse tissues after oral immunization with rSC0016(pS-SE)**

Colonization reflects the interaction between live vector and lymphoid tissues, which is closely related to the immunogenicity of the vector [33, 34]. To evaluate the colonization of rSC0016(pS-SE) in systemic lymphoid tissues, rSC0016 carrying empty vector pYA3493, single expression cassette pS-SaoA, pS-Eno, and rSC0016(pS-SE) in Nutrient broth with 0.2% L-arabinose and no 0.2% D-mannose. (ns) means that there is no significant difference between rSC0016(pS-SE) and rSC0016(pS-SaoA) or rSC0016(pS-Eno).
Serum IgG and mucosal IgA responses to SaoA or Eno
To evaluate the humoral and mucosal immune responses induced by rSC0016(pS-SE), serum antibody IgG titers or vaginal mucosal IgA titers of immunized mice were measured 3 weeks after the first immunization and 2 weeks after boosting. Compared with the PBS group or rSC0016(pYA3493) empty vector group, mice orally immunized with rSC0016(pS-SaoA), rSC0016(pS-Eno) and rSC0016(pS-SE) induced higher serum IgG and vaginal IgA titers against SaoA or Eno. Three weeks after the first immunization, the titers of serum IgG and mucosal IgA specific to SaoA or Eno induced by rSC0016(pS-SE) were similar to those of rSC0016(pS-SaoA) or rSC0016(pS-Eno) presenting a single antigen. Two weeks after the booster immunization, there was no significant difference in the specific IgG and IgA titers of SaoA between rSC0016(pS-SE) and rSC0016 (pS-SaoA) (Figures 4A and C). However, the Eno-specific IgG and IgA titers induced by rSC0016(pS-SE) were significantly lower than those induced by rSC0016(pS-Eno) (Figures 4B and D; \( P < 0.05 \)).

IgG isotype analyses
The types of immune responses induced by rSC0016(pS-SE) to SaoA or Eno were further evaluated
by measuring the levels of IgG isotype IgG1 and IgG2a. The levels of both SaoA-specific and Eno-specific IgG2a were higher than those of IgG1 (Figure 5), suggesting that both rSC0016(pS-SE) carrying a dual expression cassette and rSC0016(pS-SaoA) or rSC0016(pS-Eno) carrying a single expression cassette showed Th1-type dominant immune responses to SaoA or Eno. After booster immunization, there were no significant differences between the Eno-specific IgG1 and IgG2a between rSC0016(pS-SE) and rSC0016(pS-Eno), although rSC0016(pS-SE) induced slightly lower antibody titers than rSC0016(pS-Eno) did (Figure 5D).

**Opsonophagocytic assays**

The level of opsonizing antibodies, which can be measured by the in vitro OPA, is a better index than total serum antibody titers to reflect the vaccine-induced protection against *S. suis* [3, 35]. To further evaluate the effectiveness of antibodies induced by the rSC0016(pS-SE), the opsonizing activity of mouse serum was measured after booster immunization. The OPA antibody titers induced by rSC0016(pS-SaoA) against SS2, SS9, SS7, and SS1/2 were significantly higher than those of the empty vector rSC0016(pYA3493) (Figures 6A–D). There was no significant difference between rSC0016(pS-Eno) and empty vector rSC0016(pYA3493) although Eno
induced a slightly higher titer of OPA antibodies against SS2, SS7, and SS1/2 than that of empty vector. However, the OPA antibody titer induced by rSC0016(pS-Eno) against SS9 was significantly higher than that of empty vector rSC0016(pYA3493) (Figures 6A–D). For homologous strains, the OPA antibody titers against SS2 or SS9 induced by rSC0016(pS-SE) were significantly higher than those of rSC0016(pS-Eno) (Figures 6A and B; \(P < 0.05\)). In addition, the OPA antibody titer against SS9 induced by rSC0016(pS-SE) was significantly higher than that of strain rSC0016(pS-SaoA) (Figure 6B; \(P < 0.05\)). For heterologous strains, the OPA antibody titers against SS7 or SS1/2 induced by rSC0016(pS-SE) were significantly higher than those of rSC0016(pS-Eno) (Figures 6C and D; \(P < 0.05\)). In addition, the OPA antibody titer against SS7 induced by rSC0016(pS-SE) was significantly higher than that of rSC0016(pS-SaoA) (Figure 6B; \(P < 0.05\)).

rSC0016(pS-SE) is better at inducing a broad OPA reaction against heterologous strains than rSC0016(pS-Eno) which can only induce OPA against homologous strain (Figures 6A–C; \(P < 0.05\)). In conclusion, a synergetic effect was observed when rSC0016 delivered the dual-antigen expression cassette.

rSC0016(pS-SE) protects mice against SS2, SS7, SS9 and SS1/2 infection

To evaluate cross-protection against multiple serotypes of S. suis conferred by rSC0016(pS-SE), immunized mice were challenged with \(10 \times \text{LD}_{50}\) SS2, SS7, SS9, and SS1/2, respectively. Mice which were given PBS (blank control) or empty vector rSC0016(pYA3493) all died within 6 days after the challenge with different serotypes of S. suis. For SS2 or SS7 challenge, the survival rate of mice immunized with rSC0016(pS-SE) was significantly higher than that with rSC0016(pS-Eno) (Figures 7A, C; \(P < 0.001\)), but similar to rSC0016(pS-SaoA). For SS9 challenge, the survival rate of mice immunized with strain rSC0016(pS-SE) was significantly higher than that with strain rSC0016(pS-SaoA) (Figure 7B; \(P < 0.001\)), but similar to rSC0016(pS-Eno). For the SS1/2 challenge, the survival rate of mice immunized with strain rSC0016(pS-SE) was significantly higher than that with either strain rSC0016(pS-SaoA) or rSC0016(pS-Eno) (Figure 7D; \(P < 0.05\)). These results support the view that multiple antigens provide broader protection than a single antigen. In addition, lung tissue section analysis showed severe hyperemia and massive inflammatory exudation in mice immunized with empty vector rSC0016(pYA3493) or PBS, moderate hyperemia and a small amount of inflammatory exudation in mice immunized with rSC0016(pS-Eno) or rSC0016(pS-SaoA), and mild histopathological lesions in mice immunized with rSC0016(pS-SE) (Figures 8A and B). The analysis of brain sections showed that most of the mice were immunized with rSC0016(pYA3493) and a few mice were immunized with rSC0016(pS-Eno) or rSC0016(pS-SaoA) showed meningeal hemorrhage and neutrophil infiltration. The mice immunized with rSC0016(pS-SE) showed mild histopathological lesions (Figures 8C and D). To sum up, rSC0016(pS-SE) presenting dual expression cassette provides stronger and broader protection than rSC0016(pS-SaoA) or rSC0016(pS-Eno) presenting a single antigen.

Discussion

Vaccine strains with polyvalent antigens need to be developed to cover multiple-serotype of S. suis epidemic strains [2, 3, 18]. In this study, rSC0016(pS-SE), which integrates a dual antigen expression cassette, induces antibodies with cross-opsonophagocytic activity and provides high protection against multiple serotypes of S. suis.

For Salmonella vector, the metabolic pressure or virulence caused by foreign antigens, especially foreign
antigens with multiple expression cassettes, needs to be accurately evaluated [33]. On the one hand, it is hard to induce a robust immune response if the expression level of the foreign protein is too low. On the other, it may also cause metabolic pressure on the vector and affect the colonization of the vector in the host lymphatic system if the foreign antigen is overexpressed, which impairs the ability of the vector to induce an effective immune response [34]. Previously, we developed a regulated delayed antigen synthesis and regulated delayed attenuated system of S. Choleraesuis, which optimized the colonization and the synthesis of foreign antigens [12, 27–29]. Those studies tested the system with a single antigen. In this study, the system was used to regulate two antigens as an operon fusion. The synthesis of LacI under the arabinoase promoter gradually decreased with the decrease of arabinose (Figure 1C). Correspondingly, the production of SaoA and Eno under the Ptrc promoter regulation gradually increased (Figure 1C). The results demonstrate that both SaoA and Eno were synthesized independently in rSC0016(pS-SE). Both were under the strict control of the delayed synthesis antigen system since the same promoter regulated them. The growth rate and lymphatic tissue distribution of rSC0016(pS-SaoA) are like that of strain rSC0016(pS-SaoA) or rSC0016(pS-Eno), suggesting that the metabolic pressure of the dual expression cassette is not a concern for rSC0016(pS-SE). In summary, rSC0016(pS-SE) with an increased antigen production still achieves a balance between antigen synthesis and colonization, which could be attributed to the presence of the delayed antigen synthesis system.

The antibody titer reflects the degree to which the antigen components in the vaccine are processed and presented. It is usually positively correlated with the antigen concentration contained in the vaccine [36]. In this study, the specific antibody titers (IgG or IgA) against SaoA or

---

**Figure 6 Bactericidal assays.** Bacterial killing by murine neutrophils under opsonizing conditions. The data represent OPA antibody titers against SS2, SS7, SS9, and SS1/2 in sera from ten mice orally immunized with the indicated S. Choleraesuis strains 2 weeks after boosting. Serum from individual mouse was serially diluted with twofold to obtain titers. Error bars represent variation between mice. SS2, SS7, SS9, and SS1/2 were incubated at 37 °C with 5% serum and porcine neutrophils/polymorphonuclear leukocytes (PMNs) at a 1:1 (CFU: PMN) ratio for 1 h, and bacterial survival was determined as described in the Materials and Methods. *P < 0.05; **P < 0.001.
Eno induced by rSC0016(pS-SE) strain were significantly higher than those of the empty vector control group (Figures 4A–D) at 3- and 5- weeks after the first immunization, suggesting that rSC0016(pS-SE) strain delivering dual expression cassette could induce SaoA-specific and Eno-specific antibody responses simultaneously. Notably, the level of SaoA-specific antibody (IgG or IgA) induced by rSC0016(pS-SE) in mice is equivalent to that induced by rSC0016(pS-SaoA) (Figures 4A and C). This result demonstrates that the SaoA in rSC0016(pS-SE) retained similar immunogenicity to that in rSC0016(pS-SaoA). In this study, we observed a decrease of Eno-specific antibodies induced by rSC0016(pS-SE) compared to rSC0016(pS-Eno) at 2 weeks after the boost immunization (Figure 4D).

The result may be due to the abundant antigen stimulation brought by the dual expression cassette delivered by rSC0016(pS-SE), which leads to slight immune tolerance in the immune system of mice [37, 38]. Although it is not a significant difference, the production of Eno is slightly lower in rSC0016(pS-SE) than that in pS-Eno. This might also contribute to the lower antibody responses against Eno.

The level of opsonizing antibodies, which can be measured by the in vitro OPA, is one of the indexes to reflect the vaccine-induced protection against S. suis [3, 35]. Sao formulated with Emulsigen-Plus® failed to induce OPA antibody against SS2, or SS9 then failed to confer protection but induced OPA antibody against SS2 and conferred protection when formulated with Quil-A [5, 6]. Although antibody-mediated opsonophagocytosis is considered a good indicator of protection against S. suis [3, 4, 35], few vaccine candidates exhibit the OPA to heterologous S. suis serotype. In this study, rSC0016(pS-SaoA) not only induced OPA antibody against SS2 (Figure 6A), but also induced OPA antibodies to heterologous serotypes SS7, SS9 and SS1/2 (Figures 6B–D), demonstrating that rSC0016 is a suitable vector for SaoA, which is beneficial to enhance the immunogenicity of SaoA. Previous studies have shown that Eno-antiserum from rabbits does not exhibit OPA [39]. However, we observed in this study that rSC0016(pS-Eno) induced mice to

![Figure 7](Figure 7 Survival of immunized mice challenged with wild-type Streptococcus suis strains SS2, SS7, SS9, or SS1/2. Female BALB/c mice per group were immunized orally twice at 3-week intervals with 1 × 10^9 CFU of with attenuated Salmonella carrying either pS-SaoA, pS-Eno, pS-SE, or pYA3493 (empty vector) and PBS. Each group of mice was randomly divided into 5 subsets of ten mice each and were respectively challenged intraperitoneally with 1.2 × 10^9)
Figure 8  Histopathology of the lung and brain of the immunized mice infected with S. suis serotypes 2, 7, 9 and 1/2. Microscopic pathological observations of lung and brain of mice after challenge with S. suis serotypes 2, 7, 9 and 1/2. For lung (A), neutrophilic infiltration and interstitial thickening are shown with a black arrow. For brain (C), meningeal thickening and neutrophilic infiltration are shown with a black arrow. The experiment was performed twice. A representative figure of each group is shown (n = 10). The results from both experiments were similar and the data were pooled for analysis. Histology scores in the lung (B) and brain (D). Horizontal lines show the mean, and error bars represent the SD (n = 10). *P < 0.05; **P < 0.01.
produce OPA antibodies against SS9 (Figure 6B). This result indicated that the opsonizing activity of antigen-specific antibodies varied according to adjuvants or delivery systems [6, 40]. Animal species might also affect the OPA induced by the same antigen. Although the protein homology of Eno among these serotypes is high (Table 2), rSC0016(pS-Eno) does not induce cross-OPA antibodies against heterologous serotypes. This result indicated that the cross-reactivity of OPA antibodies might not be positively correlated with antigen conservation. The completion of detailed epitope information will allow a better understanding of the mechanism by which antibodies induce cross-OPA.

It is interesting to note that the antiserum of rSC0016(pS-SE) has a broader and more effective opsonophagocytic response than either rSC0016(pS-SaoA) or rSC0016(pS-Eno) against multiple types of S. suis (Figures 6A–D). These results may be due to rSC0016(pS-SE) induced OPA antibodies that can target two antigens. Host protection against highly encapsulated S. suis is mainly mediated by opsonophagocytosis, which is closely related to the function of IgG2a [41]. IgG2a, which marks Th1-dominant immune responses, can effectively mediate bacterial lysis through bacterial opsonophagocytosis by triggering the complement cascade [42]. In contrast, IgG1 elicited during Th2-dominant immune responses usually has a less protective potential [41, 42]. In this study, rSC0016 confers a strong Th1-dominant immune response to foreign antigens (Figures 5A–D), which may result in a broad and robust OPA response against multiple serotypes of S. suis induced by rSC0016(pS-SE).

In our previous study, high cross-protection against SS7 (80%) and SS9 (100%) was observed in mice when utilizing rSC0016 to deliver SS2-Eno [28]. In this study, rSC0016 delivers SS9-Eno confer only 20% heteroprotection against SS7 challenges. The type of signal peptide affects the synthesis and secretion of the fusion protein [49]. Antigens secreted to the extracellular of Salmonella vector are more readily recognized by antigen-presenting cells to enhance adaptive immunity [30, 49]. Previous studies have shown that the secretory effect of the OmpA signal peptide is weaker than that of the Bla/ss signal peptide [30]. Therefore, we reasonably speculate that the secretory level of SS9-Eno fused with OmpA signal peptide is likely lower than that of SS2-Eno fused with Bla/ss signal peptide, resulting in lower immunogenicity of rSC0016 carrying SS9-Eno than that of rSC0016 carrying SS2-Eno. Interestingly, there is just one amino acid difference at position 250 between the SS2-Eno and the SS9-Eno. A polar amino acid tyrosine is located at position 250 in SS2-Eno, while a non-polar amino acid phenylalanine is at position 250 in SS9-Eno. Position 250 is within the plasminogen binding site [43]. The transition from polar amino acids to non-polar amino acids often leads to a change in protein conformation [44], which could lead to antigen diversity [45]. Our results emphasize the need to test the immunogenicity of homologous antigenic proteins from different serotypes, even if they have very high homology. The protection achieved by rSC0016(pS-SE) against homologous strains SS2 and SS9 attained 100%, suggesting that dual antigen-containing rSC0016(pS-SE) retained the original immunogenicity of SaoA and Eno. Generally speaking, the more conservative the antigen, the higher the efficiency of heterogeneous protection [9, 12, 21, 28, 46, 47]. SaoA and Eno are highly conserved among the heterologous SS prevalent strains used here (Table 2). Our results showed that the combination of these two conserved antigens improves heterologous protection (Figure 7). It is possible that antigens cooperate with each other to induce an effective immune response [21, 46], or the combination of antigens with different functions provides broader protection [18, 20, 46]. The clinical symptoms of S. suis in humans are mainly meningitis [50]. In this study, we observed different degrees of hemorrhage and inflammatory cell infiltration in the brain tissue of mice in the blank control group but not in the rSC0016(pS-SE) immunized group after respectively intraperitoneal injection of SS2, SS9, SS7, and SS9 (Figures 8C, D). This suggests that rSC0016(pS-SE) has a potential against S. suis-causing meningitis. These results show that our rSC0016(pS-SE) has the potential to resist S. suis-causing meningitis, which provides a new idea for the development of vaccines against S. suis-causing meningitis in piglets and humans. Admittedly, mouse trials can only suggest the efficacy of the vaccine to a certain extent. Next step, we will carry out target animal experiments in piglets to further verify the protective efficacy of rSC0016(pS-SE). In conclusion, the recombinant attenuated vector of S. Choleraesuis rSC0016 can be used as a factory to produce multivalent antigens from different serotypes of S. suis as a vaccine to broaden the cross-protection against multiple serotypes of S. suis, which

| Table 2  | Amino acid homology of SS2-SaoA or SS9-Eno.  |
|----------|---------------------------------------------|
| Homology strains | Coverage (%) |
| SS2-SaoA VS SS9-SaoA | 98.5 |
| SS2-SaoA VS SS7-SaoA | 94.2 |
| SS2-SaoA VS SS1/2-SaoA | 100 |
| SS9-Eno VS SS2-Eno | 99.8 |
| SS9-Eno VS SS7-Eno | 99.8 |
| SS9-Eno VS SS1/2-Eno | 99.8 |
enables S. Choleraesuis vector as an effective platform to develop a multivalent vaccine.

Abbreviations
S. Choleraesuis: Salmonella enterica Serotype choleraesuis; S. suis: Streptococcus suis; Sao: surface-anchored protein; SS2: S. suis Serotype 2; SS7: S. suis Serotype 7; SS9: S. suis Serotype 9; LB: Luria broth; LD50: Lethal dose; Th1: T helper type 1; Th2: T helper type 2; PBS: phosphate buffer saline; SDS-PAGE: sodium dodecyl sulfate–polyacrylamide; MRP: muramidase-released protein; EF: extracellular factor; FCA: Freund’s complete adjuvant; OPA: opsonophagocytic activity.

Acknowledgements
We thank Dr Roy Curtiss III (Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, USA), for kindly providing χ7213, pYA3493.

Author contributions
Y-al. was responsible for implementation of the assays, interpreting the data and writing the first draft; YS, YF, and YZ were involved in certain assays; SW, QL and HS were involved in revising and editing; HS was involved in experiment design, was responsible for the interpretation of the data, monitoring the exploration process. All authors read and approved the final manuscript.

Funding
This study was supported by the National Natural Science Foundation of China (Grant Numbers 32172802, 31672516, 32002301, 31172300, 30670079), the China Postdoctoral Science Foundation (Grant Number 2019M661953), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). This study was supported by the National Natural Science Foundation of China (Grant Numbers 31572640, 31772803, 31702432, 31502632), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Availability of data and materials
The materials and data not presented in this manuscript are available from the corresponding author upon request.

Declarations
Competing interests
The authors declare that they have no competing interests.

References
1. Gottschalk M, Xu J, Calzas C, Segura M (2010) Streptococcus suis: a new emerging or an old neglected zoonotic pathogen? Future Microbiol 5:371–391
2. Goyette-Desjardins G, Auger JP, Xu J, Segura M, Gottschalk M (2014) Streptococcus suis, an important pig pathogen and emerging zoonotic agent—an update on the worldwide distribution based on serotyping and sequence typing. Emer Microbes Infect 3:e45
3. Segura M (2015) Streptococcus suis vaccines: candidate antigens and progress. Expert Rev Vaccines 14:1587–1608
4. Kock C, Beineke A, Setz M, Ganter M, Walldmann KH, Valentin-Weigand P, Baums CG (2009) Intranasal immunization with a live Streptococcus suis isogenic ofs mutant elicited sialylin-neutralization titers but failed to induce opsonizing antibodies and protection. Vet Immunol Immunopathol 132:135–145
5. Baums CG, Kock C, Beineke A, Bennecke K, Goethe R, Schroder C, Walldmann KH, Valentin-Weigand P (2009) Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9. Clin Vaccine Immunol 16:200–208
6. Li Y, Gottschalk M, Esglesas M, Lacouture S, Dubreuil JD, Willson P, Harel J (2007) Immunization with recombinant Saa protein confers protection against Streptococcus suis infection. Clin Vaccine Immunol 14:937–943
7. Dekker CN, Bouma A, Daemen AJ, van Leengoed LA, Jonker FH, Wage‑naar JA, Stegeman JA (2012) Homologous whole bacterin vaccination is not able to reduce Streptococcus suis serotype 9 strain 7997 transmission among pigs or colonization. Vaccine 30:1379–1387
8. Buttnr N, Beineke A, de Buhr N, Lilienthal S, Merkell J, Walldmann KH, Valentin-Weigand P, Baums CG (2012) Streptococcus suis serotype 9 bacterin immunogenicity and protective efficacy. Vet Immunol Immunopathol 146:191–200
9. Weisse C, Dittmar D, Jakobczak B, Florian V, Schutze N, Alber G, Klose K, Michalk S, Valentin-Weigand P, Volker U, Baums CG (2021) Immunogenicity and protective efficacy of a Streptococcus suis vaccine composed of six conserved immunogens. Vet Res 52:112
10. Lee SE, Kim SY, Jeong BC, Kim YR, Bae SJ, Ahn OS, Lee JJ, Song HC, Kim JM, Cho YH, Chung SS, Kweon MN, Rhe JH (2008) A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 74:694–702
11. Hseueh KJ, Lee JW, Hou SM, Chen HS, Chang TC, Chu CY (2014) Evaluation on a Streptococcus suis vaccine using recombinant sao-I protein manufactured by bioreactors as the antigen in pigs. Transbound Emerg Dis 61:e35–e43
12. Li Y, Ji Z, Wang X, Wang S, Shi H (2017) Salmonella enterica serovar Choleraesuis vector delivering Saio antigen confers protection against Streptococcus suis serotypes 2 and 7 in mice and pigs. Vet Res 48:89
13. Zhang A, Chen B, Mu X, Li R, Zheng P, Zhao Y, Chen H, Jin M (2009) Identification and characterization of a novel protective antigen, Enolase of Streptococcus suis serotype 2. Vaccine 27:1348–1353
14. Jiang X, Yang Y, Zhou J, Liu H, Liao X, Luo Li, X, Fang W (2019) Peptidyl isomerase PrnA is surface-associated on Streptococcus suis and offers cross-protection against serotype 9 strain. FEMS Microbiol Lett 366:fnz002
15. Rivera-Hernandez T, Rhyme MS, Cork AJ, Jones S, Segui-Perez C, Lawrenz M, Goldblatt D, Collin N, Walker MJ, Kaufmann SHE (2020) Vaccine-induced Th1-type response protects against invasive group A Streptococcus infection in the absence of opsonizing antibodies. Mbio 11:e120–e122
16. Esglesas M, Li Y, Hancock MA, Harel J, Dubreuil JD, Gottschalk M (2008) Isolation and characterization of α-enolase, a novel fibronectin-binding protein from Streptococcus suis. Microbiology 154:2668–2679
17. Olin P, Rasmussen F, Gustafsson I, Hallander HO, Heijbel H (1997) Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc group for the study of pertussis vaccines. Lancet 350:1569–1577
18. Zhang S, Sella M, Santirri J, Priegue P, Shen D, Seeberger PH (2021) Discovery of oligosaccharide antigens for semi-synthetic glycoconjugate vaccine leads against Streptococcus suis serotypes 2, 3, 9 and 14*. Angew Chem Int Ed Engl 60:14679–14692
19. Wisseling HJ, Verdt UJ, Stockhofe-Zurwieden N, Smith HE (2001) Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine. Vet Rec 148:473–477
20. Marin-Lopez A, Otero-Romero I, de la Poza F, Menaya-Vargas R, Calvo-Agüero M, Casas J, de la Calle A, Pérez-Díaz A, Giné S, Pumarola M, Valdivieso J, Miret J (2000) NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi vaccine leads against Streptococcus suis serotypes 2, 3, 9 and 14*. Angew Chem Int Ed Engl 60:14679–14692
21. Welsch JA, Granoff D, Rappuoli R, Pizza M (2006) A universal vaccine for meningococcemia in meningococcal serogroup B meningococcus. Proc Natl Acad Sci USA 103:14679–14692
22. Wisseling HJ, Verdt UJ, Stockhofe-Zurwieden N, Smith HE (2001) Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine. Vet Rec 148:473–477
23. Marin-Lopez A, Otero-Romero I, de la Poza F, Menaya-Vargas R, Calvo-Agüero M, Casas J, de la Calle A, Pérez-Díaz A, Giné S, Pumarola M, Valdivieso J, Miret J, Welsch JA, Granoff D, Rappuoli R, Pizza M (2006) A universal vaccine for meningococcemia in meningococcal serogroup B meningococcus. Proc Natl Acad Sci USA 103:10834–10839

Page 14 of 15

Li et al. Veterinary Research (2022) 53:46
